Over the past year, the food allergy world has seen some truly exciting momentum—from new treatment approaches to innovative ways to deliver life-saving epinephrine. One breakthrough that has sparked a lot of conversation is the first FDA-approved epinephrine nasal spray, offering the first needle-free option for emergency allergic reactions. We’re thrilled to welcome someone at the center of this innovation: Rich Lowenthal, Co-founder, President, and CEO of ARS Pharma—the company behind neff...
All content for FAACT's Roundtable is the property of FAACT's Roundtable Podcast and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Over the past year, the food allergy world has seen some truly exciting momentum—from new treatment approaches to innovative ways to deliver life-saving epinephrine. One breakthrough that has sparked a lot of conversation is the first FDA-approved epinephrine nasal spray, offering the first needle-free option for emergency allergic reactions. We’re thrilled to welcome someone at the center of this innovation: Rich Lowenthal, Co-founder, President, and CEO of ARS Pharma—the company behind neff...
Ep. 249: Experiencing Food Allergy through Different Lenses
FAACT's Roundtable
16 minutes
2 months ago
Ep. 249: Experiencing Food Allergy through Different Lenses
FAACT’s Vice President of Inclusion Initiatives, Aleasa Word, recently wrote a powerful piece reminding us that no two people experience food allergies the same way. We’re honored to have Aleasa with us to explore a fresh perspective—one that not only captures the lived experience of food allergies, but also sparks greater empathy, awareness, and understanding in the communities around us. Resources to keep you in the know: Read FAACT’s BlogsYou can find FAACT's Roundtable Podcast on Apple Po...
FAACT's Roundtable
Over the past year, the food allergy world has seen some truly exciting momentum—from new treatment approaches to innovative ways to deliver life-saving epinephrine. One breakthrough that has sparked a lot of conversation is the first FDA-approved epinephrine nasal spray, offering the first needle-free option for emergency allergic reactions. We’re thrilled to welcome someone at the center of this innovation: Rich Lowenthal, Co-founder, President, and CEO of ARS Pharma—the company behind neff...
